These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36884358)

  • 1. A multidimensional pan-cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma.
    Wei S; Lu K; Xing J; Yu W
    FASEB J; 2023 Apr; 37(4):e22849. PubMed ID: 36884358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma.
    Wei S; Xing J; Chen J; Chen L; Lv J; Chen X; Li T; Yu T; Wang H; Wang K; Yu W
    J Exp Clin Cancer Res; 2024 Jan; 43(1):3. PubMed ID: 38163876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pan-Cancer Crosstalk Between the
    Xie R; Yuan M; Jiang Y
    Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic value and immunological role of FOXM1 in human solid tumors.
    Wei G; Yang X; Lu H; Zhang L; Wei Y; Li H; Zhu M; Zhou X
    Aging (Albany NY); 2022 Nov; 14(22):9128-9148. PubMed ID: 36435510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance.
    Chen W; Li X; Jiang Y; Ni D; Yang L; Wu J; Gao M; Wang J; Song J; Shi W
    Sci Rep; 2023 Nov; 13(1):19209. PubMed ID: 37932473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [N
    Wang J; Zhao X; Lu Y; Fan D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Dec; 38(12):1069-1077. PubMed ID: 36585228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
    Yang W; Han B; Chen Y; Geng F
    Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.
    Wang Y; Chen R; Zhang J; Zeng P
    PLoS One; 2024; 19(4):e0299949. PubMed ID: 38635758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.